Evidence map›Paper›PMID 32968209›Full record

ArticleActa pharmacologica Sinica2021

Targeted inhibition of calpain in mitochondria alleviates oxidative stress-induced myocardial injury.

Dong Zheng, Ting Cao, Lu-Lu Zhang, Guo-Chang Fan, Jun Qiu, Tian-Qing Peng

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Increased Intermembrane Space [CaCirculation research · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Calpain and Cardiometabolic Diseases.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Dong Zheng *Centre of Clinical Laboratory, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Ting Cao *Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China.
Lu-Lu ZhangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China.
Guo-Chang FanDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.
Jun QiuCentre of Clinical Laboratory, the First Affiliated Hospital of Soochow University, Suzhou 215006, China. 13606136542@126.com.
Tian-Qing PengInstitutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China. tqpeng@suda.edu.cn.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNUniversity of Cincinnati Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein levels and activities of calpain-1 and calpain-2 are increased in cardiac mitochondria under pathological conditions including ischemia, diabetes, and sepsis, and transgenic overexpression of mitochondrial-targeted calpain-1 induces dilated heart failure, which underscores an important role of increased calpain in mitochondria in mediating myocardial injury. However, it remains to be determined whether selective inhibition of calpain in mitochondria protects the heart under pathological conditions. In this study, we generated transgenic mice overexpressing mitochondrial-targeted calpastatin in cardiomyocytes. Their hearts were isolated and subjected to global ischemia/reperfusion. Hyperglycemia was induced in the transgenic mice by injections of STZ. We showed that transgenic calpastatin was expressed exclusively in mitochondria isolated from their hearts but not from other organs including skeletal muscle and lung tissues. Transgenic overexpression of mitochondrial-targeted calpastatin significantly attenuated mitochondrial oxidative stress and cell death induced by global ischemia/reperfusion in isolated hearts, and ameliorated mitochondrial oxidative stress, cell death, myocardial remodeling and dysfunction in STZ-treated transgenic mice. The protective effects of mitochondrial-targeted calpastatin were correlated with increased ATP5A1 protein expression and ATP synthase activity in isolated hearts subjected to global ischemia/reperfusion and hearts of STZ-treated transgenic mice. In cultured rat myoblast H9c2 cells, overexpression of mitochondrial-targeted calpastatin maintained the protein levels of ATP5A1 and ATP synthase activity, prevented mitochondrial ROS production and decreased cell death following hypoxia/reoxygenation, whereas upregulation of ATP5A1 or scavenging of mitochondrial ROS by mito-TEMPO abrogated mitochondrial ROS production and decreased cell death. These results confirm the role of calpain in myocardial injury, suggesting that selective inhibition of calpain in myocardial mitochondria by mitochondrial-targeted calpastatin is an effective strategy for alleviating myocardial injury and dysfunction in cardiac pathologies.

Indexed as

AnimalsApoptosisCalcium-Binding ProteinsCalpainCardiomegalyDiabetes Mellitus, ExperimentalFibrosisMaleMice, TransgenicMitochondria, HeartMitochondrial Proton-Translocating ATPasesMyocytes, CardiacOxidative StressReactive Oxygen SpeciesATP5A1 protein, mouseCalcium-Binding ProteinsCalpaincalpastatinMitochondrial Proton-Translocating ATPasesReactive Oxygen SpeciesATP synthasecalpaincalpastatinglobal ischemia-reperfusionhearthyperglycemiamitochondriamyocardial injuryoxidative stress

Identifiers

PMID32968209
PMCPMC8149722
OpenAlexW3088124181

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.